PMEL and cancer: The references identified and their corresponding experimentally-derived epitopes can be broadly classified into the following areas (15); mutated (e.g. neoantigens), oncoviral (e.g. HPV), cancer germline antigens (e.g. MAGE, PRAME, NY-ESO-1), differentiation or tissue-specific antigens (e.g. MART-1, gp100, CEA, prostate antigens), and overexpressed antigens (e.g. Her2/neu, Survivin, wildtype p53).